Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut 2020; 69: 859–867.
Published: 15th October 2020
Authors: El-Salhy M, Hatlebakk JG, Gilja OH, Kristoffersen AB, Hausken T
Some 165 patients were randomized to a placebo, or one of two groups with different amounts of microbiota. A 50-point reduction in IBS score was recorded in 23.6 per cent of controls, versus 76.9 per cent in patients who had 30g microbiota and 89.1 per cent who had 60g (both P<0.001).Pubmed Link
You may also be interested in
Luglio G, Rispo A, Imperatore N, Giglio MC, Amendola A, Tropeano FP et al. Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s Disease: the SuPREMe-CD Study – A Randomized Clinical Trial. Ann Surg 2020; 272: 210-217.
Authors: Luglio G , Rispo A, Imperatore N, Giglio MC, Amendola A, Tropeano FP et al.
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet 2020; 395: 1927-1936.
Authors: The HALT-IT Trial Collaborators
Prophylactic angiographic embolisation after endoscopic control of bleeding to high-risk peptic ulcers: a randomised controlled trial. Gut 2019; 68: 796-803
Authors: Lau JYW, Pittayanon R, Wong K-T, Pinjaroen N, Chiu PWY, Rerknimitr R et al.
A prospective randomized controlled trial of laparoscopic repair versus open repair for perforated peptic ulcers. Surgery 2016; 159: 451–458.
Authors: Ge B, Wu M, Chen Q, Chen Q, Lin R, Liu L et al.
Double oral esomeprazole after a 3-day intravenous esomeprazole infusion reduces recurrent peptic ulcer bleeding in high-risk patients: a randomised controlled study. Gut 2014; 63: 1864-1872.
Authors: Cheng HC, Wu CT, Chang WL, Cheng WC, Chen VVY, Sheu BS et al.
Multinational, double-blind, randomised, placebo controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut 2014; 63: 1061-1068.
Authors: Sugano K, Choi M-G, Lin J-T, Goto S, Okada Y, Kinoshita Y et al. et al.
Enhanced postoperative recovery pathways in emergency surgery: a randomised clinical trial. Am J Surg 2014; 207: 807-814.
Authors: Gonenc M, Dural AC, Celik F, Akarsu C, Kocatas A, Kalayci MU et al. et al.
Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63: 244-249.
Authors: McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio G, Ducons J et al. et al.
Authors: Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C et al. et al.
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2012; 381: 205–213.
Authors: Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ et al. et al.
Randomized clinical trial of vessel sealing system (LigaSure) in esophagogastric devascularisation and splenectomy in patients with portal hypertension. Am J Surg 2011; 41: 82-90.
Authors: Yao SH, Wang WJ, Wang Q, Gao WC, Xiang HG, Hu ZQ et al. et al.
Novel approach to antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): randomised controlled trial. BMJ 2010; 340: 81.
Authors: Blomberg J, Lagergren P, Martin L, Mattsson F, Lagergren J.